Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 04, 2017 12:00 ET | Source: Idera Pharmaceuticals, Inc.

Idera to Present at the 35th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. and EXTON, Pa., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
November 28, 2016 07:00 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals and Vivelix Pharmaceuticals, Ltd. Enter Into Exclusive License Agreement for the Worldwide Rights to IMO-9200

CAMBRIDGE, Mass., EXTON, Pa. and HAMILTON, Bermuda, Nov. 28, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), and Vivelix Pharmaceuticals, Ltd. today announced that they have...
November 11, 2016 15:15 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Reports Translational Data Supporting the Mechanism of Action of Intratumoral IMO-2125 from Ongoing Phase 1 Dose Escalation in Clinical Trial in Combination with Ipilimumab in Metastatic Melanoma Patients Refractory to Anti-PD-1 Treatment

CAMBRIDGE, Mass. and EXTON, Pa., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
November 10, 2016 07:30 ET | Source: Idera Pharmaceuticals, Inc.

Idera to Present at the Stifel 2016 Healthcare Conference

CAMBRIDGE, Mass. and EXTON, Pa., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
November 09, 2016 07:30 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals to Provide Multiple Presentations on Intratumoral IMO-2125 at the 2016 Society for Immunotherapy of Cancer (SITC) Annual Meeting

CAMBRIDGE, Mass. and EXTON, Pa., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
October 28, 2016 07:30 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Reports Third Quarter 2016 Financial Results

CAMBRIDGE, Mass. and EXTON, Pa., Oct. 28, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and...
October 07, 2016 09:04 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass. and EXTON, Pa., Oct. 07, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) (“Idera” or the “Company”) today announced the pricing of an underwritten public offering...
October 05, 2016 16:00 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass. and EXTON, Pa., Oct. 05, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) (“Idera” or the “Company”) today announced that it intends to offer and sell up to...
September 27, 2016 07:30 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Presents New Third Generation Antisense (3GA) Data at the 12th Annual Meeting of the Oligonucleotide Therapeutics Society

CAMBRIDGE, Mass. and EXTON, Pa., Sept. 27, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and...
September 27, 2016 03:23 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals宣布针对PD-1难治型黑色素瘤患者所进行的肿瘤内IMO-2125及Ipilimumab结合疗法1期剂量递增临床试验取得理想结果

– 3位PD-1难治型黑色素瘤患者病情有所缓解，其中1位患者已完全有效 –– 为重点专注于IMO-2125的临床开发，公司暂停开发B细胞淋巴癌治疗药物IMO-8400 –麻萨诸塞州剑桥及宾夕法尼亚州埃克斯顿, Sept. 27, 2016 (GLOBE NEWSWIRE) --...